Mortality from Parkinson's disease: A population-based prospective study (NEDICES)

Movement Disorders

Volumn 26, Issue 14, 2011, Pages 2522-2529

  Posada, Ignacio J ^a,b   Benito León, Julián ^a,b,c   Louis, Elan D ^d,e,f   Trincado, Rocío ^a,c   Villarejo, Alberto ^a,b   Medrano, María José ^g   Bermejo Pareja, Félix ^a,b,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^e ISCIII ^*  (United States)

^f NONE   (United States)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Elderly; Epidemiology; Mortality; Parkinson's disease

Indexed keywords

AGED; ARTICLE; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DATA COLLECTION; FEMALE; HUMANS; LUNG DISEASES; MALE; NEOPLASMS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 83555178502     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23921     Document Type: Article

References (45)

1. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutcj WJ. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand. 1990; 81: 294-299.
2. Kuroda K, Tatara K, Takatorige T, Shinsho F. Effect of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand. 1992; 86: 55-59.
3. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology. 1993; 43: 1918-1926.
4. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry. 1995; 58: 293-299.
5. Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand. 1995; 92: 55-58.
6. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996; 334: 71-76.
7. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996; 46: 1044-1050.
8. Tison F, Letenneur L, Djossou F, Dartigues JF. Further evidence of increased risk of mortality of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996; 60: 592-593.
9. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol. 1997; 54: 260-264.
10. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol. 1998; 43: 318-325.
11. Hely MA, Morris JGL, Traficante R, Reid WGJ, O'sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999; 67: 300-307.
12. Berger K, Breteler MM, Helmer C, et al. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology. 2000; 54( 11 Suppl 5): S24-S27.
13. Donnan PT, Steinke DT, Stubbings C, Davey PG, McDonald TM. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology. 2000; 55: 1785-1789.
14. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival. A population-based study. Arch Neurol. 2000; 57: 507-512.
15. Guttman M, Slaughter PM, Theriault ME, De Boer DP, Math M, Naylor CD. Parkinsonism in Ontario. Increased mortality compared with controls in a large cohort study. Neurology. 2001; 57: 2278b2282.
16. Montastruc J-L, Desboeuf K, Lapeyre-Mestre M, Senard J, Rascol O, Brefel-Courbon C. Long-Term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord. 2001; 16: 511-514.
17. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc. 2002; 77: 918-925.
18. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002; 59: 1708-1713.
19. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 2003; 60: 91-96.
20. Fall PA, Saleh A, Fredrickson M, Olsson JE, Granérus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord. 2003; 18: 1312-1316.
21. Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease. A community based study. Neurology. 2004; 62: 937-942.
22. Hughes TA, Ross HF, Mindham RHS, Spokes EGS. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand. 2004; 110: 118-123.
23. De Lau L, Schipper C, Hofman A, Koudstaal PJ, Breteler M. Prognosis of Parkinson disease. Risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005; 62: 1265-1269.
24. Hely M, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005; 20: 190-199.
25. Marras C, McDermott MP, Rochon PA, et al. The Parkinson Study Group. Survival in Parkinson disease. Thirteen-year follow-up of the DATATOP cohort. Neurology. 2005; 64: 87-93.
26. D'Amelio M, Ragonese P, Morgante L, et al. Long-term survival of Parkinson's disease: a population-based study. J Neurol. 2006; 253: 33-37.
27. Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006; 21: 1002-1007.
28. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008; 23: 837-844.
29. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson's disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008; 70: 1423-1430.
30. Diem-Zangerl A, Seppi K, Wenning GK, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord. 2009; 24: 819-825.
31. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM; Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003; 18: 267-274.
32. Benito-León J, Bermejo-Pareja F, Morales-González JM, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004; 62: 734-741.
33. Benito-León J, Bermejo-Pareja F, Louis ED; Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence of essential tremor in three elderly populations of central Spain. Neurology. 2005; 64: 1721-1725.
34. Díaz-Guzmán J, Bermejo-Pareja F, Benito-León J, Vega S, Gabriel R, Medrano MJ; Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of stroke and transient ischemic attack in three elderly populations of central Spain. Neuroepidemiology. 2008; 30: 247-253.
35. Martínez-Salio A, Benito-León J, Díaz-Guzmán J, Bermejo-Pareja F. Cerebrovascular disease incidence in central Spain (NEDICES): a population-based prospective study. J Neurol Sci. 2010; 298: 85-90.
36. Bermejo-Pareja F, Benito-León J, Vega S, et al. Consistency of clinical diagnosis of dementia in NEDICES: a population-based longitudinal study in Spain. J Geriatr Psychiatry Neurol. 2009; 22: 246-255.
37. Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC; Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008; 264: 63-72.
38. Bermejo F, Gabriel R, Vega S, Morales JM, Rocca WA, Anderson DW. Problems and issues with door-to-door, two-phase surveys: an illustration from central Spain. Neuroepidemiology. 2001; 20: 225-231.
39. Morales JM, Bermejo FP, Benito-León J, et al; NEDICES Study Group. Methods and demographic findings of the baseline survey of the NEDICES cohort: a door-to-door survey of neurological disorders in three communities from central Spain. Public Health. 2004; 118: 426-433.
40. Bermejo-Pareja F, Benito-León J, Vega-Q S, et al. La cohorte de ancianos NEDICES. Metodología y principales hallazgos neurológicos. Rev Neurol. 2008; 46: 416-423.
41. Vega S, Benito-León J, Bermejo-Pareja F, et al. Several factors influenced attrition in a population-based elderly cohort: neurological disorders in Central Spain Study. J Clin Epidemiol. 2010; 63: 215-222.
42. Fahn S, Elton R; Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987: 153-163.
43. Louis ED, Benito-León J, Bermejo-Pareja F; Neurological Disorders in Central Spain (NEDICES) Study Group. Self-reported depression and anti-depressant medication use in essential tremor: cross-sectional and prospective analyses in a population-based study. Eur J Neurol. 2007; 14: 1138-1146.
44. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967; 17: 427-442
45. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.